HIV Prevention Clinical Trial
— TOPAZOfficial title:
Pharmacy-based PrEP for Young Women Who Sell Sex in Zimbabwe
Pharmacy-based PrEP for Young Women who Sell Sex in Zimbabwe is a cluster-randomized control trial and pilot study co-led by Dr. Euphemia Sibanda, Reader (Associate Professor) of Global Health and Epidemiology at Liverpool School of Tropical Medicine, UK and Research Director at the Centre for Sexual Health and HIV Research (CeSHHAR Zimbabwe) and Dr. Sandra McCoy, Professor of Epidemiology and Biostatistics at the University of California, Berkeley. The goal of the proposed study is to optimize, refine and pilot a pharmacy-based PrEP intervention for female sex workers (FSW) in Zimbabwe. Despite efforts to reach the most impacted and vulnerable populations with PrEP, retention rates, particularly among FSW in Africa, are very low. Relatively high levels of uptake indicate that FSW are interested in PrEP and ready to initiate it, but in most cases fewer than 50% of those who initiate return for medication refills by month 4. Pharmacy-based PrEP has the potential to address known barriers to PrEP retention among FSW such as stigma and access, and coupled with a small escalating incentive in the form of a gift card incentive, could also boost motivation for effective use of PrEP.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2025 |
Est. primary completion date | March 11, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - 1) Exchanged sexual intercourse for money or gifts in past 6 months - 2) Age 16 or older - 3) HIV negative (via rapid test per national guidelines) at enrollment and no signs/symptoms of acute HIV infection |
Country | Name | City | State |
---|---|---|---|
Zimbabwe | CESHHAR Zimbabwe | Harare |
Lead Sponsor | Collaborator |
---|---|
University of California, Berkeley | Centre for Sexual Health and HIV/AIDS Research Zimbabwe (CeSHHAR Zimbabwe), Liverpool School of Tropical Medicine, University of California, San Francisco |
Zimbabwe,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | PrEP retention at 6 months among FSW who are 18-24 years of age | : PrEP retention at 6 months among FSW who are 18-24 years of age, stratified by pickup location. This will be measured as attendance within one week (before and after) of the scheduled refill visit at the 6-month visit. Outcome 2 will also be measured as follows: Proportion of visits completed as scheduled, by arm. | 6 months | |
Other | : PrEP retention at 6 months among participants who have remained active in sex work | PrEP retention at 6 months among participants who have remained active in sex work (based on program, referral app and microplanner data). This will be measured as attendance within one week (before and after) of the scheduled refill visit at the 6-month visit. Outcome 3 will also be measured as follows: Proportion of visits completed as scheduled, by arm. | 6 months | |
Other | FSW (overall) and FSW (18-24 years) patronage for PrEP services at pharmacies | FSW (overall) and FSW (18-24 years) patronage for PrEP services at pharmacies, defined as the proportion of PrEP refill pick-ups in intervention suburbs occurring at pharmacies. | 9 months | |
Other | HIV tests | The number and outcomes of HIV tests at the time of refill. | 9 months | |
Other | HIV care referrals | This outcome will measure the number of referrals for HIV care. | 9 months | |
Primary | PrEP retention at 6 months | This will be measured as attendance within one week (before and after) of the scheduled refill visit at the 6-month visit. Outcome 1 will also be measured as follows: Proportion of visits completed as scheduled, by arm. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03411577 -
Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program
|
N/A | |
Active, not recruiting |
NCT03112369 -
Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use
|
N/A | |
Not yet recruiting |
NCT03642314 -
HIV Self-testing in Implementation PrEP Study
|
N/A | |
Completed |
NCT01810315 -
Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity
|
Phase 1 | |
Completed |
NCT00984971 -
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
|
Phase 1 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Active, not recruiting |
NCT03255915 -
PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)
|
Early Phase 1 | |
Completed |
NCT05037513 -
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
|
N/A | |
Recruiting |
NCT05087680 -
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
|
N/A | |
Recruiting |
NCT05804461 -
Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico
|
N/A | |
Completed |
NCT03148171 -
Project WERK (Wellness Encouragement Respect Kinship)
|
N/A | |
Completed |
NCT04791007 -
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
|
Early Phase 1 | |
Recruiting |
NCT05412433 -
Clinic-based HIV Identification and Prevention Project Using Electronic Resources
|
N/A | |
Active, not recruiting |
NCT03977181 -
The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms
|
N/A | |
Recruiting |
NCT05165745 -
Stick2PrEP Cisgender Women and Trans Individuals
|
N/A | |
Completed |
NCT03719053 -
Single Dose Truvada Study
|
Phase 1 | |
Recruiting |
NCT03856580 -
Long-acting Biomedical HIV Prevention in Transgender Women
|
N/A | |
Completed |
NCT02750540 -
Optimization of a Tenofovir Enema for HIV Prevention
|
Phase 1 | |
Completed |
NCT01386294 -
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
|
Phase 3 | |
Completed |
NCT00993811 -
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
|
Phase 1 |